Interstitial lung disease before and after COVID-19: a double threat?
Authors:
Open Access
- 2 December 2021
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (6) , 2101956
Abstract
Pre-existing ILD and pulmonary fibrosis increases the risk to manifest severe COVID-19. Residual interstitial lung changes and sequelae have been observed in COVID-19 survivors. A closer and standardised long-term follow-up of these patients is needed.https://bit.ly/3jWBPCGKeywords
This publication has 26 references indexed in Scilit:
- Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysisRespiratory Medicine, 2020
- Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapyThe Lancet Respiratory Medicine, 2020
- Pulmonary fibrosis secondary to COVID-19: a call to arms?The Lancet Respiratory Medicine, 2020
- Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DADHistopathology, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort studyBMJ, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Follow-up chest radiographic findings in patients with MERS-CoV after recoveryIndian Journal of Radiology and Imaging, 2017
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group ReportAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CTLa radiologia medica, 2011